PMS-RAMIPRIL-HCTZ TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

RAMIPRIL; HYDROCHLOROTHIAZIDE

Предлага се от:

PHARMASCIENCE INC

АТС код:

C09BA05

INN (Международно Name):

RAMIPRIL AND DIURETICS

дозиране:

10.0MG; 12.5MG

Лекарствена форма:

TABLET

Композиция:

RAMIPRIL 10.0MG; HYDROCHLOROTHIAZIDE 12.5MG

Начин на приложение:

ORAL

Броя в опаковка:

30/100

Вид предписание :

Prescription

Терапевтична област:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Каталог на резюме:

Active ingredient group (AIG) number: 0251649003; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2010-02-02

Данни за продукта

_pms-RAMIPRIL-HCTZ (ramipril/hydrochlorothiazide) _
_Page 1 of 67_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-RAMIPRIL-HCTZ
Ramipril and Hydrochlorothiazide Tablets
Tablets, 10/12.5 mg, 10/25 mg, Oral
Angiotensin Converting Enzyme Inhibitor Plus Diuretic
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
Submission Control Number: 273262
Date of Initial Approval:
January 21, 2010
Date of Revision:
June 20, 2023
_pms-RAMIPRIL-HCTZ (ramipril/hydrochlorothiazide) _
_Page 2 of 67_
RECENT MAJOR LABEL CHANGES
7 WARNING AND PRECAUTIONS, Ophthalmologic
10/2021
7 WARNING AND PRECAUTIONS, Respiratory
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
...............................................................................................
2
TABLE OF CONTENTS
.................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................................
4
1
INDICATIONS
.......................................................................................................................
4
2
CONTRAINDICATIONS
..........................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.....................................................................
5
4
DOSAGE AND ADMINISTRATION
..........................................................................................
5
4.1
Dosing Considerations
......................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................................. 6
4.4
Administration
............................................................................................................